Corrigendum to: The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib (British Journal of Haematology, (2013), 161, 1, (43-56), 10.1111/bjh.12206);The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib

British Journal of Haematology

Volumn 161, Issue 1, 2013, Pages 43-56

  Dasmahapatra, Girija ^a   Patel, Hiral ^a   Dent, Paul ^a,b,c   Fisher, Richard I ^d   Friedberg, Jonathan ^d   Grant, Steven ^a,b,c  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Bortezomib; Bruton tyrosine kinase; Diffuse large B cell lymphoma; Mantle cell lymphoma; PCI 32765

Indexed keywords

BORTEZOMIB; BRUTON TYROSINE KINASE INHIBITOR; CD34 ANTIGEN; DNA; HISTONE H2AX; I KAPPA B ALPHA; IBRUTINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INITIATION FACTOR 2ALPHA; PROTEASOME INHIBITOR; PROTEIN BCL XL; PROTEIN BCL2L1; PROTEIN KINASE B; PROTEIN MCL 1; PROTEIN NFKB1; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL ACTIVATION; DNA DAMAGE; DOWN REGULATION; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; ENZYME INACTIVATION; GERMINAL CENTER; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LYMPHOMA CELL; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION;

EID: 84875055944     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.15766     Document Type: Erratum

References (62)

1. Adams, J., Palombella, V.J., Sausville, E.A., Johnson, J., Destree, A., Lazarus, D.D., Maas, J., Pien, C.S., Prakash, S. & Elliott, P.J. (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Research, 59, 2615-2622.
2. An, B., Goldfarb, R.H., Siman, R. & Dou, Q.P. (1998) Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death and Differentiation, 5, 1062-1075.
3. Balbasubramanian, S., Crowley, S., Sirisiwad, M., Thiemann, P., Chen, J. & Buggy, J. (2011) The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Inhibits Growth of ABC DLBCL Tumors In Vivo and in Vitro by Preventing Activation of Pro-Survival NF-{kappa}B pathways. Blood (ASH annual Meeting Abstracts), 117, 4969.
4. Bea, S., Zettl, A., Wright, G., Salaverria, I., Jehn, P., Moreno, V., Burek, C., Ott, G., Puig, X., Yang, L., Lopez-Guillermo, A., Chan, W.C., Greiner, T.C., Weisenburger, D.D., Armitage, J.O., Gascoyne, R.D., Connors, J.M., Grogan, T.M., Braziel, R., Fisher, R.I., Smeland, E.B., Kvaloy, S., Holte, H., Delabie, J., Simon, R., Powell, J., Wilson, W.H., Jaffe, E.S., Montserrat, E., Muller-Hermelink, H.K., Staudt, L.M., Campo, E. & Rosenwald, A. (2005) Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood, 106, 3183-3190.
5. Bedford, L., Lowe, J., Dick, L.R., Mayer, R.J. & Brownell, J.E. (2011) Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nature reviews. Drug discovery, 10, 29-46.
6. Castillo, J.J., Furman, M. & Winer, E.S. (2012) CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opinion on Investigational Drugs, 21, 15-22.
7. Celeste, A., Petersen, S., Romanienko, P.J., Fernandez-Capetillo, O., Chen, H.T., Sedelnikova, O.A., Reina-San-Martin, B., Coppola, V., Meffre, E., Difilippantonio, M.J., Redon, C., Pilch, D.R., Olaru, A., Eckhaus, M., Camerini-Otero, R.D., Tessarollo, L., Livak, F., Manova, K., Bonner, W.M., Nussenzweig, M.C. & Nussenzweig, A. (2002) Genomic instability in mice lacking histone H2AX. Science, 296, 922-927.
8. Chen, K.F., Yeh, P.Y., Yeh, K.H., Lu, Y.S., Huang, S.Y. & Cheng, A.L. (2008) Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Research, 68, 6698-6707.
9. Chou, T.C. & Talalay, P. (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation, 22, 27-55.
10. Compagno, M., Lim, W.K., Grunn, A., Nandula, S.V., Brahmachary, M., Shen, Q., Bertoni, F., Ponzoni, M., Scandurra, M., Califano, A., Bhagat, G., Chadburn, A., Dalla-Favera, R. & Pasqualucci, L. (2009) Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature, 459, 717-721.
11. Craxton, A., Jiang, A., Kurosaki, T. & Clark, E.A. (1999) Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt. Journal of Biological Chemistry, 274, 30644-30650.
12. Dai, Y., Rahmani, M. & Grant, S. (2003) Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. Oncogene, 22, 7108-7122.
13. Dai, Y., Rahmani, M., Dent, P. & Grant, S. (2005) Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Molecular and Cellular Biology, 25, 5429-5444.
14. Dasmahapatra, G., Lembersky, D., Rahmani, M., Kramer, L., Friedberg, J., Fisher, R.I., Dent, P. & Grant, S. (2009) Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. Cancer Biology & Therapy, 8, 808-819.
15. Dasmahapatra, G., Lembersky, D., Kramer, L., Fisher, R.I., Friedberg, J., Dent, P. & Grant, S. (2010) The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood, 115, 4478-4487.
16. Dasmahapatra, G., Lembersky, D., Son, M.P., Attkisson, E., Dent, P., Fisher, R.I., Friedberg, J.W. & Grant, S. (2011) Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Molecular Cancer Therapeutics, 10, 1686-1697.
17. Dasmahapatra, G., Lembersky, D., Son, M.P., Patel, H., Peterson, D., Attkisson, E., Fisher, R.I., Friedberg, J.W., Dent, P. & Grant, S. (2012) Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo. Molecular Cancer Therapeutics, 11, 1122-1132.
18. Datta, S.R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y. & Greenberg, M.E. (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 91, 231-241.
19. Datta, S.R., Brunet, A. & Greenberg, M.E. (1999) Cellular survival: a play in three Akts. Genes & Development, 13, 2905-2927.
20. Davis, R.E., Ngo, V.N., Lenz, G., Tolar, P., Young, R.M., Romesser, P.B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., Xu, W., Shaffer, A.L., Wright, G., Xiao, W., Powell, J., Jiang, J.K., Thomas, C.J., Rosenwald, A., Ott, G., Muller-Hermelink, H.K., Gascoyne, R.D., Connors, J.M., Johnson, N.A., Rimsza, L.M., Campo, E., Jaffe, E.S., Wilson, W.H., Delabie, J., Smeland, E.B., Fisher, R.I., Braziel, R.M., Tubbs, R.R., Cook, J.R., Weisenburger, D.D., Chan, W.C., Pierce, S.K. & Staudt, L.M. (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature, 463, 88-92.
21. Dunleavy, K., Pittaluga, S., Czuczman, M.S., Dave, S.S., Wright, G., Grant, N., Shovlin, M., Jaffe, E.S., Janik, J.E., Staudt, L.M. & Wilson, W.H. (2009) Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood, 113, 6069-6076.
22. Fisher, R.I., Bernstein, S.H., Kahl, B.S., Djulbegovic, B., Robertson, M.J., de, V.S., Epner, E., Krishnan, A., Leonard, J.P., Lonial, S., Stadtmauer, E.A., O'Connor, O.A., Shi, H., Boral, A.L. & Goy, A. (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology, 24, 4867-4874.
23. Gao, N., Rahmani, M., Dent, P. & Grant, S. (2005) 2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process. Oncogene, 24, 3797-3809.
24. Goy, A., Younes, A., McLaughlin, P., Pro, B., Romaguera, J.E., Hagemeister, F., Fayad, L., Dang, N.H., Samaniego, F., Wang, M., Broglio, K., Samuels, B., Gilles, F., Sarris, A.H., Hart, S., Trehu, E., Schenkein, D., Cabanillas, F. & Rodriguez, A.M. (2005) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology, 23, 667-675.
25. Harrison, C. (2012) Trial watch: BTK inhibitor shows positive results in B cell malignancies. Nature reviews. Drug discovery, 11, 96.
26. Herman, S.E., Gordon, A.L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K.A., Buggy, J.J., Hamdy, A., Johnson, A.J. & Byrd, J.C. (2011) Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood, 117, 6287-6296.
27. Hideshima, T., Ikeda, H., Chauhan, D., Okawa, Y., Raje, N., Podar, K., Mitsiades, C., Munshi, N.C., Richardson, P.G., Carrasco, R.D. & Anderson, K.C. (2009) Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood, 114, 1046-1052.
28. Honigberg, L.A., Smith, A.M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D.H., Miller, R.A. & Buggy, J.J. (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proceedings of the National Academy of Sciences of the United States of America, 107, 13075-13080.
29. Hu, J., Dang, N., Menu, E., De, B.E., Xu, D., Van, C.B., Van, V.E. & Vanderkerken, K. (2012) Activation of ATF4 mediates the unwanted Mcl-1 accumulation by proteasome inhibition. Blood, 119, 826-37.
30. Hussain, A., Yu, L., Faryal, R., Mohammad, D.K., Mohamed, A.J. & Smith, C.I. (2011) TEC family kinases in health and disease - loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK. FEBS Journal, 278, 2001-2010.
31. Ikeda, H., Hideshima, T., Fulciniti, M., Perrone, G., Miura, N., Yasui, H., Okawa, Y., Kiziltepe, T., Santo, L., Vallet, S., Cristea, D., Calabrese, E., Gorgun, G., Raje, N.S., Richardson, P., Munshi, N.C., Lannutti, B.J., Puri, K.D., Giese, N.A. & Anderson, K.C. (2010) PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood, 116, 1460-1468.
32. Jia, L., Gopinathan, G., Sukumar, J.T. & Gribben, J.G. (2012) Blocking autophagy prevents bortezomib-induced NF-kappaB activation by reducing I-kappaBalpha degradation in lymphoma cells. PLoS One, 7, e32584.
33. Jung, H.J., Chen, Z., Fayad, L., Wang, M., Romaguera, J., Kwak, L.W. & McCarty, N. (2012) Bortezomib-resistant nuclear factor kappaB expression in stem-like cells in mantle cell lymphoma. Experimental Hematology, 40, 107-118.
34. Khalil, A.M., Cambier, J.C. & Shlomchik, M.J. (2012) B cell receptor signal transduction in the GC is short-circuited by high phosphatase activity. Science, 336, 1178-1181.
35. Kim, A.H., Khursigara, G., Sun, X., Franke, T.F. & Chao, M.V. (2001) Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Molecular and Cellular Biology, 21, 893-901.
36. Kim, A., Park, S., Lee, J.E., Jang, W.S., Lee, S.J., Kang, H.J. & Lee, S.S. (2012) The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells. Leukemia Research, 36, 912-920.
37. Lam, L.T., Davis, R.E., Pierce, J., Hepperle, M., Xu, Y., Hottelet, M., Nong, Y., Wen, D., Adams, J., Dang, L. & Staudt, L.M. (2005) Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clinical Cancer Research, 11, 28-40.
38. Lin, J.H., Li, H., Yasumura, D., Cohen, H.R., Zhang, C., Panning, B., Shokat, K.M., Lavail, M.M. & Walter, P. (2007) IRE1 signaling affects cell fate during the unfolded protein response. Science, 318, 944-949.
39. Ling, Y.H., Liebes, L., Zou, Y. & Perez-Soler, R. (2003) Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. Journal of Biological Chemistry, 278, 33714-33723.
40. Lopez-Guerra, M. & Colomer, D. (2010) NF-kappaB as a therapeutic target in chronic lymphocytic leukemia. Expert opinion on therapeutic targets, 14, 275-288.
41. Mohamed, A.J., Yu, L., Backesjo, C.M., Vargas, L., Faryal, R., Aints, A., Christensson, B., Berglof, A., Vihinen, M., Nore, B.F. & Smith, C.I. (2009) Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunological Reviews, 228, 58-73.
42. Mujtaba, T. & Dou, Q.P. (2011) Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discovery medicine, 12, 471-480.
43. Nencioni, A., Grunebach, F., Patrone, F., Ballestrero, A. & Brossart, P. (2007) Proteasome inhibitors: antitumor effects and beyond. Leukemia, 21, 30-36.
44. Obeng, E.A., Carlson, L.M., Gutman, D.M., Harrington, W.J. Jr, Lee, K.P. & Boise, L.H. (2006) Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood, 107, 4907-4916.
45. O'Brien, S., Buger, J.A., Blum, K.A., Furman, R.R., Coutre, S.E., Sharman, J., Flinn, I.W., Grant, B., Heerema, N.A., Johnson, A.J., Navarro, T., Holmgren, E., Hedrick, E. & Byrd, J.C. (2011) The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): follow-up of a Phase Ib/II Study. Blood (ASH annual Meeting Abstracts), 118, 983.
46. Orlowski, R.Z., Small, G.W. & Shi, Y.Y. (2002) Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. Journal of Biological Chemistry, 277, 27864-27871.
47. Rahmani, M., Davis, E., Crabtree, T., Habibi, J., Nguyen, T., Dent, P. & Grant, S. (2007) The kinase inhibitor sorafenib induces cell death through a process involving induction of ER stress. Molecular and Cellular Biology, 27, 5499-5413.
48. Rawlings, D.J., Scharenberg, A.M., Park, H., Wahl, M.I., Lin, S., Kato, R.M., Fluckiger, A.C., Witte, O.N. & Kinet, J.P. (1996) Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science, 271, 822-825.
49. Richardson, P.G., Mitsiades, C., Hideshima, T. & Anderson, K.C. (2006) Bortezomib: proteasome inhibition as an effective anticancer therapy. Annual Review of Medicine, 57, 33-47.
50. Staudt, L.M. & Dave, S. (2005) The biology of human lymphoid malignancies revealed by gene expression profiling. Advances in Immunology, 87, 163-208.
51. Staudt, L., Dunleavy, K., Buggy, J., Hedrick, E., Lucas, N., Pittaluga, S., Javar, S., Schmidt, R., Williams, M., Lih, J., Jaffe, E. & Wilson, W. (2011) The Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 Modulates Chronic Active BCR Signaling and Induces Tumor Regression in Relapsed/Refractory ABC DLBCL. Blood (ASH annual Meeting Abstracts), 118, 2716.
52. Stommel, J.M., Kimmelman, A.C., Ying, H., Nabioullin, R., Ponugoti, A.H., Wiedemeyer, R., Stegh, A.H., Bradner, J.E., Ligon, K.L., Brennan, C., Chin, L. & DePinho, R.A. (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science, 318, 287-290.
53. Takada, Y. & Aggarwal, B.B. (2004) Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. Journal of Biological Chemistry, 279, 4750-4759.
54. Teske, B.F., Wek, S.A., Bunpo, P., Cundiff, J.K., McClintick, J.N., Anthony, T.G. & Wek, R.C. (2011) The eIF2 kinase PERK and the integrated stress response facilitate activation of ATF6 during endoplasmic reticulum stress. Molecular Biology of the Cell, 22, 4390-4405.
55. Toulany, M., Kasten-Pisula, U., Brammer, I., Wang, S., Chen, J., Dittmann, K., Baumann, M., Dikomey, E. & Rodemann, H.P. (2006) Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Clinical Cancer Research, 12, 4119-4126.
56. Wang, L., Martin, P., Blum, K., Kahl, B., Maeda, L., Advani, R., Williams, M., Rule, S., Rodriguez, S., Pang, C., Hedrick, E. & Goy, A. (2011) The Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously treated mantle cell lymphoma: preliminary results of a phase II trial. Blood (ASH annual Meeting Abstracts), 118, 442.
57. Weniger, M.A., Rizzatti, E.G., Perez-Galan, P., Liu, D., Wang, Q., Munson, P.J., Raghavachari, N., White, T., Tweito, M.M., Dunleavy, K., Ye, Y., Wilson, W.H. & Wiestner, A. (2011) Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clinical Cancer Research, 17, 5101-5112.
58. Wickremasinghe, R.G., Prentice, A.G. & Steele, A.J. (2011) Aberrantly activated anti-apoptotic signalling mechanisms in chronic lymphocytic leukaemia cells: clues to the identification of novel therapeutic targets. British Journal of Haematology, 153, 545-556.
59. Williams, M.E., Connors, J.M., Dreyling, M.H., Gascoyne, R.D., Kahl, B.S., Leonard, J.P., Press, O.W. & Wilson, W.H. (2011) Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. Leukaemia & Lymphoma, 52, 24-33.
60. Xu, C., Bailly-Maitre, B. & Reed, J.C. (2005) Endoplasmic reticulum stress: cell life and death decisions. The Journal of clinical investigation, 115, 2656-2664.
61. Yeramian, A., Sorolla, A., Velasco, A., Santacana, M., Dolcet, X., Valls, J., Abal, L., Moreno, S., Egido, R., Casanova, J.M., Puig, S., Vilella, R., Llombart-Cussac, A., Matias-Guiu, X. & Marti, R.M. (2012) Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway. International Journal of Cancer, 130, 967-978.
62. Yu, C., Rahmani, M., Dent, P. & Grant, S. (2004) The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Experimental Cell Research, 295, 555-566.